Skip to content
Search

Latest Stories

NICE says 'highly effective' breast cancer drug is 'too expensive' for NHS use

Sacituzumab govitecan, a 'highly effective' treatment for triple negative breast cancer, is not recommended by the National Institute for Health and Care Excellence (NICE) for NHS use.

“The current price of the drug is too expensive to be considered a cost-effective use of NHS resources,” the agency said in a draft guidance published on April 7.


NICE already recommends atezolizumab with chemotherapy, the only other targeted treatment for this type of breast cancer.

NICE is looking at sacituzumab govitecan (also called Trodelvy and made by Gilead Sciences) for treating triple negative breast cancer which can’t be removed surgically and has spread nearby from where it started (locally advanced) or has spread to other parts of the body (metastatic). It is used after people have had two or more prior lines of systemic therapies, at least one of them for unresectable locally advanced or metastatic disease.

Because triple-negative breast cancer is not sensitive to hormone therapy or molecular targeted therapy, the usual treatment is chemotherapy. The aim of treatment is to stop the disease getting worse, extend life, and maintain or improve quality of life for as long as possible.

Sacituzumab govitecan is an antibody (sacituzumab) that works by targeting the activity of proteins that are present at high levels on the surface of tumour cells. By targeting these proteins it delivers the anti-cancer component of the drug directly to tumour cells, preventing them from multiplying and eventually causing them to die.

Helen Knight, interim director of medicines evaluation at NICE, said: “Because sacituzumab govitecan is a highly effective treatment, and given the lack of treatment options for people with this type of breast cancer, we’re very disappointed that its price means we can’t recommend it for use in the NHS at this point.

“We hope that the company will consider what it can do to enable NICE to approve a treatment that has the potential to give people with advanced triple negative breast cancer more time with their loved ones.”

Triple negative breast cancer can be more aggressive than other types of breast cancer and accounts for a quarter of all deaths from breast cancer despite accounting for only one in five cases. It is estimated there are around 2,000 people in England with triple negative breast cancer, of whom around 650 would have been eligible for treatment with sacituzumab govitecan if NICE had recommended it.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less